Trius Therapeutics

Last updated

Trius Therapeutics (Nasdaq :  TSRX) was a biopharma company based in San Diego, CA that focused on the development of antibiotics. [1]

Contents

Business profile

The lead compound from Trius, tedizolid phosphate (formerly torezolid phosphate, TR-701), successfully completed its first Phase 3 clinical trial (ESTABLISH 1) in acute skin and skin structure infections (ABSSSI). [2] It is a once daily, IV and oral, oxazolidinone being developed for the treatment of serious grampositive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). [3] The Phase 3 trials are being conducted under a Special Protocol Agreement with the US Food and Drug Administration and are using the draft FDA guidance of cessations of lesion spread at 48–72 hours as the primary endpoint. [4] In the ESTABLISH 1 Study, 200 mg of Tedizolid given for a short course of therapy (six days) was shown to be safe, well tolerated and was as effective as the traditional length of therapy with linezolid (600 mg for ten days). [5] Additionally, Tedizolid was shown to have fewer treatment-related side effects than linezolid and significantly fewer GI side effects. [6]

Trius was planning the second Phase 2 trial and expects to report results around the end of Q1 2013 and planned to submit an NDA to the FDA for the drug in the second half of 2013. [7]

Tedizolid was approved by the US Food and Drug Administration on June 20, 2014.

The firm was acquired by Cubist Pharmaceuticals at the end of July 2013 in a deal worth $1.6 billion. This fee also included the purchase of Optimer Pharmaceuticals. [8]

Funding

In February 2007 Trius was formed (formerly Rx3) in conjunction with a Series A financing. [9] Trius completed an initial public offering in August 2010, raising $50 million. [10] Its stock was added to the NASDAQ Biotechnology Index in 2012. [11]

Partnerships and Government Contracts

In 2008 the company received a $28 million contract from the National Institute of Allergy and Infectious Diseases a component of the National Institutes of Health, to develop antibiotics against gram-negative infections. The work included a collaboration with the Lawrence Livermore National Laboratory to help identify antibiotics against gram-negative infections and bioterrorism. [12] Trius was awarded a contract by Lawrence Livermore National Laboratory in 2011 for $3 million. [13] In 2011 Bayer acquired the exclusive rights to Trius' antibiotic tedizolid in certain areas in Asia, Africa, the Middle East, and Latin America. [14] The deal was reported as being worth $94 million. [15]

Employees

Trius was founded by the last Chief Financial Officer John Schmid and Chief Scientific Officer John Finn. [16] Other executives included Chief Executive Officer Jeffrey Stein, Chief Medical Officer Philippe Prokocimer, Chief Commercial Officer Craig Thompson, [17] and Chief Development Officer Ken Bartizal. [18] The Chairman of the Board is David Kabakoff. [19] The company today has 83 full-time employees. [20]

Related Research Articles

Methicillin-resistant <i>Staphylococcus aureus</i> Bacterium responsible for difficult-to-treat infections in humans

Methicillin-resistant Staphylococcus aureus (MRSA) is a group of Gram-positive bacteria that are genetically distinct from other strains of Staphylococcus aureus. MRSA is responsible for several difficult-to-treat infections in humans. It caused more than 100,000 deaths attributable to antimicrobial resistance in 2019.

Linezolid Antibiotic medication

Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant Staphylococcus aureus (MRSA). The main uses are infections of the skin and pneumonia although it may be used for a variety of other infections including drug-resistant tuberculosis. It is used either by injection into a vein or by mouth.

Cefalexin Beta-lactam antibiotic

Cefalexin, also spelled cephalexin, is an antibiotic that can treat a number of bacterial infections. It kills gram-positive and some gram-negative bacteria by disrupting the growth of the bacterial cell wall. Cefalexin is a beta-lactam antibiotic within the class of first-generation cephalosporins. It works similarly to other agents within this class, including intravenous cefazolin, but can be taken by mouth.

Glycopeptide antibiotic

Glycopeptide antibiotics are a class of drugs of microbial origin that are composed of glycosylated cyclic or polycyclic nonribosomal peptides. Significant glycopeptide antibiotics include the anti-infective antibiotics vancomycin, teicoplanin, telavancin, ramoplanin and decaplanin, corbomycin, complestatin and the antitumor antibiotic bleomycin. Vancomycin is used if infection with methicillin-resistant Staphylococcus aureus (MRSA) is suspected.

John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.

Dalbavancin

Dalbavancin, sold under the brand names Dalvance in the US and Xydalba in the EU among others, is a second-generation lipoglycopeptide antibiotic medication. It belongs to the same class as vancomycin, the most widely used and one of the treatments available to people infected with methicillin-resistant Staphylococcus aureus (MRSA).

Biomedical Advanced Research and Development Authority Government organization in Washington D.C., United States

The Biomedical Advanced Research and Development Authority(BARDA) is a U.S. Department of Health and Human Services (HHS) office responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases. BARDA was established in 2006 through the Pandemic and All-Hazards Preparedness Act (PAHPA) and reports to the Office of the Assistant Secretary for Preparedness and Response (ASPR). The office manages Project BioShield, which funds the research, development and stockpiling of vaccines and treatments that the government could use during public health emergencies such as chemical, biological, radiological or nuclear (CBRN) attacks.

Tedizolid Oxazolidinone-class antibiotic

Tedizolid, is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics, and is marketed for the treatment of acute bacterial skin and skin structure infections.

Deutsche Hospitality

Deutsche Hospitality is the umbrella brand of the German hotel company Steigenberger Hotels AG, member of the Huazhu Group since 2020. In January 2020, Deutsche Hospitality's portfolio included a total of around 150 hotels on three continents, of which more than 30 are under construction or in planning. The hotels of the brands Steigenberger Hotels & Resorts, MAXX by Steigenberger, Jaz in the City, IntercityHotel and Zleep Hotels are located in 19 countries, including Germany, Austria, Switzerland, the Netherlands, Belgium, Denmark, Sweden, Spain, Egypt, Qatar, Oman, Tunisia, the United Arab Emirates and China. In 2019, the hotel group announced its worldwide expansion plan, which aims to increase the global portfolio to 250 hotels by 2024.

Skin and skin structure infections (SSSIs), also referred to as skin and soft tissue infections (SSTIs), or acute bacterial skin and skin structure infections (ABSSSIs), are infections of skin and associated soft tissues. Historically, the pathogen involved has most frequently been a bacterial species—always, since redescription of SSSIs as ABSSSIs—and as such, these infections require treatment by antibiotics.

Taksta is a front-loaded oral dosing regimen of sodium fusidate under development in the U.S. as an antibiotic for gram-positive infections including drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).

Cubist Pharmaceuticals Defunct American pharmaceutical company

Cubist Pharmaceuticals was an American biopharmaceutical company that targeted pathogens like MRSA.

T3 Technion Technology Transfer

T3 Technion Technology Transfer is the technology transfer unit of the Technion – Israel Institute of Technology in Israel. The unit operates under the auspices of the Technion Research & Development Foundation.

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Pernix Therapeutics was a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market.

Guardia di Finanza Italian law enforcement agency

The Guardia di Finanza is an Italian law enforcement agency under the authority of the Minister of Economy and Finance. It is a militarized police force, forming a part of the Ministry of Economy and Finance, not the Ministry of Defence. Guardia di Finanza is essentially responsible for dealing with financial crime and smuggling; it has also evolved into Italy's primary agency for suppressing the illegal drug trade. It maintains over 600 boats and ships and more than 100 aircraft to serve in its mission of patrolling Italy's territorial waters. They also have the rule of border police and customs duties at Italian airports.

Optimer Pharmaceuticals Inc was a biopharmaceutical company, originally headquartered in San Diego, California and later moved to Jersey City, New Jersey, United States of America.

Michael Bonney

Michael "Mike" Weston Bonney is an American businessman and former pharmaceutical executive. Bonney was the president and chief executive officer of Cubist Pharmaceuticals, from 2003 until his retirement in 2014 coinciding with the company being acquired by Merck & Co. for $9.5 billion.

OTL-103 (GSK-2696275) is a gene therapy for Wiskott–Aldrich syndrome, a rare primary immunodeficiency caused by mutations in the gene that codes for Wiskott–Aldrich syndrome protein (WASp). It was developed by Orchard Therapeutics in conjunction with GlaxoSmithKline. It is currently undergoing Phase I/II of clinical trials that are expected to conclude in October 2025.

References

  1. "Trius Therapeutics - About". Triusrx.com. Retrieved 26 July 2012.
  2. http://seekingalpha.com/article/821901-an-investment-update-on-trius-therapeutics-tedizolid.{{cite web}}: Missing or empty |title= (help)
  3. http://www.nasdaq.com/article/trius-therapeutics-announces-data-presentations-on-tedizolid---quick-facts-20120911-01047.{{cite web}}: Missing or empty |title= (help)
  4. http://seekingalpha.com/article/821901-an-investment-update-on-trius-therapeutics-tedizolid.{{cite web}}: Missing or empty |title= (help)
  5. http://www.fiercebiotech.com/story/trius-shares-surge-antibiotic-matches-zyvox-pivotal-phiii/2011-12-19.{{cite web}}: Missing or empty |title= (help)
  6. http://smithonstocks.com/component/content/article/3/261-trius-therapeuticsarsquo-tedizolid-has-blockbuster-potential-for-mrsa-infections-tsrx-505.{{cite web}}: Missing or empty |title= (help)
  7. Darcé, Keith (31 October 2011). "Trius grows as lead antibiotic moves forward". San Diego Union-Tribune. Retrieved 5 September 2012.
  8. Vrinda Manocha and Zeba Siddiqui (30 July 2013). "Cubist to pay up to $1.6 billion for two antibiotics makers". Reuters.
  9. http://www.fiercebiotech.com/special-reports/emerging-drug-developer-trius-therapeutics.{{cite web}}: Missing or empty |title= (help)
  10. Scholer, Kristen; Spears, Lee (3 August 2010). "Trius Therapeutics Initial Offer Raises $50 Million". Bloomberg.
  11. "Semi-Annual Changes to the NASDAQ Biotechnology Index". MarketWatch. Retrieved 27 July 2012.
  12. Timmermeyer, Luke (22 October 2008). "Trius Therapeutics Wins $28M Contract From NIH For Bioterror Antibiotics". Xconomy. Retrieved 5 September 2012.
  13. https://web.archive.org/web/20120420044649/https://www.reuters.com/finance/stocks/TSRX.O/key-developments/article/2291312. Archived from the original on April 20, 2012.{{cite news}}: Missing or empty |title= (help)
  14. Conover, Damien (3 September 2012). "Premium Articles 5 Big Pharma Opportunities in Emerging Markets". Morning Start. Retrieved 5 September 2012.
  15. Darcé, Keith (27 July 2012). "Trius signs $94 million licensing deal for lead antibiotic". San Diego Union-Tribune. Retrieved 5 September 2012.
  16. "Trius Therapeutics Inc". Bloomberg News. Retrieved 5 September 2012.
  17. https://www.sec.gov/Archives/edgar/data/1356857/000119312512115086/d270282d10k.htm.{{cite web}}: Missing or empty |title= (help)
  18. https://www.sec.gov/Archives/edgar/data/1356857/000119312512115086/d270282d10k.htm.{{cite web}}: Missing or empty |title= (help)
  19. "Trius Therapeutics, Inc. Executives". Hoover's. Retrieved 5 September 2012.
  20. "Company Overview of Trius Therapeutics, Inc". Businessweek. Retrieved 5 September 2012.